Outcome
    Preliminary

    Curcumin for Amyloid Plaque Prevention

    Curcumin binds amyloid-beta and reduces plaque in animal models, but human trials are small and hampered by poor bioavailability.

    Overview

    Curcumin binds amyloid-beta and reduces plaque in animal models, but human trials are small and hampered by poor bioavailability.

    Verdict

    Insufficient evidence

    Strong preclinical anti-amyloid data has not translated into convincing human outcomes.

    How It Works

    Curcumin binds amyloid-beta aggregates, inhibits fibril formation in vitro, and downregulates NF-kB-driven neuroinflammation.

    Dosing & Protocol

    Typical dose

    Recommended dose
    No established dose — evidence is insufficient. Alzheimer's trials used 2-4 g/day curcumin or 180 mg/day of a bioavailable form, with no plaque benefit.
    Expected timeframe
    No benefit demonstrated over 6-18 months

    Protocol

    dose
    Not established
    form
    Curcumin (Theracurmin 90 mg twice daily and 2-4 g/day plain curcumin were studied)
    steps
    Evidence is insufficient: randomised trials in Alzheimer's disease using 2-4 g/day curcumin, and 18-month trials of 180 mg/day Theracurmin, did not show reduced amyloid plaque or clinical benefit,Plain curcumin is poorly absorbed and reaches the brain in very low concentrations,Do not take curcumin expecting to prevent or clear amyloid plaque,For cognitive risk reduction, prioritise blood pressure, hearing, sleep, exercise and metabolic health
    timing
    n/a
    duration
    Trials ran 6-18 months

    Evidence

    What the studies say

    Rodent models show clear reductions in plaque burden. Human trials have been small and inconsistent: an 18-month study of a bioavailable formulation in non-demented adults reported improved memory and reduced amyloid and tau PET signal in the amygdala and hypothalamus, but the sample was around 40 people and has not been replicated. Earlier trials using poorly absorbed curcumin found nothing.

    Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults

    Score: 6/10
    2016
    rct

    Curcumin produced small acute and chronic improvements in working memory and mood in healthy older adults.

    View source

    Safety

    Caveats

    Insufficient evidence. Curcumin can increase bleeding risk with warfarin, clopidogrel or DOACs, may trigger gallbladder pain in gallstone disease, and rare idiosyncratic liver injury is reported. Avoid therapeutic doses in pregnancy.

    Less likely to help if

    Not applicable — no benefit was shown in the trial populations.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.